Experience with itraconazole in cryptococcosis and aspergillosis

M. A. Viviani, A. M. Tortorano, M. Langer, M. Almaviva, C. Negri, S. Cristina, S. Scoccia, R. De Maria, R. Fiocchi, P. Ferrazzi, A. Goglio, G. Gavazzeni, G. Faggian, R. Rinaldi, P. Cadrobbi

Research output: Contribution to journalArticlepeer-review

Abstract

Cryptococcosis and aspergillosis in immunocompromised patients are extremely difficult clinical conditions to manage and treatment with available antifungal drugs often fails. Itraconazole, R-51211, Janssen Pharmaceutica, a new orally absorbed triazole, is a possible alternative drug which is potentially effective and nontoxic. Preliminary experience with 28 patients, eight with cryptococcosis and 20 with aspergillosis, is reported. Of these patients, 16 were immunocompromised (seven with the acquired immune-deficiency syndrome (AIDS), five heart transplant recipients and four with leukaemia or lymphoma). Overall, results of treatment were good (18 in remission, four markedly improved, four moderately improved and two failed). Prevention of relapses of cryptococcosis was obtained in all patients with AIDS on long-term itraconazole monotherapy (3 mg/kg). Treatment of invasive aspergillosis required a higher dosage (about 5 mg/kg) and prolonged administration. Besides its efficacy this antifungal agent allowed outpatient management.

Original languageEnglish
JournalJournal of Infection
Volume18
Issue number2
DOIs
Publication statusPublished - 1989

ASJC Scopus subject areas

  • Applied Microbiology and Biotechnology
  • Microbiology
  • Parasitology
  • Virology
  • Immunology and Allergy
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Experience with itraconazole in cryptococcosis and aspergillosis'. Together they form a unique fingerprint.

Cite this